Case Report
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 26, 2022; 10(18): 6227-6233
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6227
Figure 1
Figure 1 Imaging examinations. A: Computed tomography image for neuroendocrine tumor. The orange arrow indicates a focal asymmetric reinforcement area of 11 mm × 14 mm of 145 HU in the head of the pancreas; B and C: Endoscopic ultrasound images indicating the presence of a homogeneous hypoechoic semioval tumoral lesion in the pancreas, with well-defined borders measuring 2.1 cm × 1.2 cm, in close apposition to the main pancreatic duct and splenomesenteric confluence without evidence of invasion.
Figure 2
Figure 2 Histology and immunohistochemistry of the tumor. A: Hematoxylin and eosin photomicrograph (40 ×) showing neoplastic cells presenting uniformly round nuclei with granular chromatin (salt and pepper image), typical of neuroendocrine cells with extensive eosinophilic cytoplasm; B and C: Photomicrographs of immunohistochemical staining for chromogranin (B) and synaptophysin (C) (10 ×). Neoplastic cells show strong immunopositivity for both markers in the cytoplasm, which corroborates the neuroendocrine lineage of the neoplasia; D: Immunohistochemical staining for Ki67 (cell proliferation index). Strong nuclear immunopositivity is seen in approximately 4% of neoplastic cells. The tumor was classified as grade 2, according to the 2019 WHO classification.